U.S. spot Ether (ETH) ETFs experienced net outflows totaling about $1 billion over the three weeks ending October 16, surpassing the $690 million inflows recorded in the prior five sessions through September 25. Weekly outflows were $138 million, $542 million, and $320 million for the weeks ending October 2, 9, and 16 respectively. BlackRock’s iShares Ethereum Trust (ETHA) accounted for $299 million of the outflows in the last week. Despite these outflows, cumulative net inflows remain near $13 billion after October 16. These ETF flow figures reflect fund activity but do not represent all Ether market trading.
Ether ETF withdrawals reached about $1 billion over three weeks ending October 16, following $690 million inflows in late September. For readers following the cryptocurrency market, here is Pluang's snapshot as of Oct 19, 2026 15:02 WIB: 41 of 50 major cryptocurrencies rose today. EOS gained 8.13% to Rp12.649, CRV rose 5.16% with a 57% buy order activity, and UNI increased 2.94% to Rp133.479.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
